Savara (NASDAQ: SVRA) reported Q3 EPS of ($0.30), $0.10 better than the analyst estimate of ($0.40).

“Based on the totality of evidence, we continue to believe that Molgradex has a clinically meaningful treatment effect on aPAP and we are committed to this program,” said Rob Neville, Chief Executive Officer, Savara. “In the near-term, gaining clarity on the best regulatory path forward is our highest corporate priority and we look forward to further collaborating with the FDA and EMA in this regard.”

For earnings history and earnings-related data on Savara (SVRA) click here.